ReviewMolecular biology reports2026
Mechanistic insights into anti-parkinson effect of baicalein: from neuroinflammation and cell death to neurogenesis and synaptic plasticity.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a neurodegenerative disorder of the central nervous system, affecting both motor and non-motor systems. It's pathophysiology consists of a complicated process that needs to be analyzed carefully to comprehend and treat the condition adequately. Neuronal loss in PD has been attributed to neuroinflammation and oxidative stress. The primary force of the progression of synucleinopathy in the brain is the inflammatory microenvironment. Moreover, neuroinflammation also predisposes the dopamine neurons to degeneration. Additionally, oxidative stress induced by reactive oxygen species evokes the vicious cycle, which culminates in the degeneration of dopaminergic neurons in the nigra pars compacta. Currently, there are no viable treatments that could prevent or delay the neurodegenerative process of PD. Flavonoids have emerged as potentially useful naturally occurring multi-targeted agents against neurodegenerative processes. Baicalein is a trihydroxyflavone that is mainly present in the roots of Scutellaria baicalensis Georgi (Chinese skullcap). At the preclinical level, it has shown promise in alleviating PD through the modulation of inflammatory, oxidative stress, apoptotic, and autophagy-related pathways. Baicalein has been reported to modulate different mediators, including TLR4, MAPK, NF-κB, NLRP3-inflammosomes, BDNF, TrkB, ROS, AMPK, dopamine, antioxidant enzymes, proinflammatory mediators, apoptotic and antiapoptotic proteins, among others, to confer protection against PD. Thus, given the multifaceted interaction of various mediators in the pathophysiology of PD, and the potential of baicalein to regulate these processes, the current review has been structured to examine the mechanisms by which baicalein can produce its antiparkinsonian effects.
Indexed as
Identifiers
42418146What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.